<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04200144</url>
  </required_header>
  <id_info>
    <org_study_id>2837</org_study_id>
    <nct_id>NCT04200144</nct_id>
  </id_info>
  <brief_title>Endoscopic Sleeve Gastroplasty for Obesity and Microbiota Randomized Trial</brief_title>
  <acronym>ESGORT</acronym>
  <official_title>An Open-label, Randomized, Controlled Clinical Trial on the Effects of Endoscopic Sleeve Gastroplasty on Weight, Metabolic Risk Factors, Quality of Life, Satiety, Gastrointestinal Motility and Gut Microbiota</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional, open-label, randomized (2:1), standard medical therapy-controlled
      trial.

      Subjects in the standard therapy group will be given the opportunity to undergo the active
      endoscopic treatment after 6 months of follow up (open label extension) if they will not
      achieve an adequate result on body weight. All patients will be followed until the planned
      end of the study after 36 months from the ESG procedure.

      To study the effects of endoscopic gastroplasty on weight, metabolic risk factors, quality of
      life, satiety, gastrointestinal motility and gut microbiota compared to standard medical
      treatment control group.

      Primary endpoint:

      - Total body weight loss (%)

      Secondary endpoints:

        -  Metabolic risk factors (e.g. lipid profile) and anthropometric measurements (e.g hip and
           waist circumference)

        -  Body composition

        -  Quality of life

        -  Gastroesophageal reflux disease

        -  Non-Alcoholic Fatty Liver Disease (NAFLD)

        -  Non- Alcoholic-Steato-Hepatitis (NASH)

        -  Satiety

        -  Gut microbiota

      Exploratory endpoints:

        -  Gut hormones e.g. glucagon-like peptide 1, PYY and ghrelin

        -  Gastrointestinal motility
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2020</start_date>
  <completion_date type="Anticipated">December 2, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total body weight loss</measure>
    <time_frame>12 months</time_frame>
    <description>Total body weight loss (%) measurement in kg and BMI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total body weight loss</measure>
    <time_frame>36 months</time_frame>
    <description>Total body weight loss (%) measurement in kg and BMI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-Alcoholic Fatty Liver Disease evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Non-Alcoholic Fatty Liver Disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non- Alcoholic-Steato-Hepatitis evaluation</measure>
    <time_frame>12 months</time_frame>
    <description>Non- Alcoholic-Steato-Hepatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiota characterization</measure>
    <time_frame>6 months</time_frame>
    <description>Gut microbiota</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation for Gastroesophageal reflux disease</measure>
    <time_frame>12, 24, 36 months</time_frame>
    <description>Gastroesophageal reflux disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut hormones e.g. glucagon-like peptide 1, PYY and ghrelin dosages</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Gut hormones e.g. glucagon-like peptide 1, PYY and ghrelin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>performing of gastric emptying scintigraphy for gastrointestinal motility</measure>
    <time_frame>Baseline and six months</time_frame>
    <description>Gastrointestinal motility evaluation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <condition>Endoscopic Sleeve Gastroplasty</condition>
  <condition>Gastric Motility</condition>
  <condition>Gastric Hormones</condition>
  <condition>Microbiota</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>active endoscopic treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients that will undergo Endoscopic Sleeve Gastroplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard medical therapy control diet group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients that will undergo diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endoscopic sleeve gastroplasty</intervention_name>
    <description>Endoscopic sleeve gastroplasty with Overstitch (Apollo Endosurgery)</description>
    <arm_group_label>active endoscopic treatment</arm_group_label>
    <arm_group_label>standard medical therapy control diet group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The participants have to fulfill the following criteria for participating in the study:

          -  Age 20 to 65 years

          -  BMI between 30 to 45 kg/m2

          -  Willingness to participate in the study and ability to comply and understand the study
             protocol

        Exclusion Criteria:

        Active gastric ulcer during the last 6 months

          -  Organic or motility disorder of the stomach and / or esophagus

          -  Anticoagulant treatment

          -  Previous bariatric surgery or any other type of surgery of the esophagus, stomach and
             duodenum

          -  Ongoing or active malignancy during the last 5 years

          -  Myocardial infarction during the past 6 months or/and heart failure class III or IV
             according to the New York Heart association's classification

          -  Drug or alcohol abuse

          -  Bulimic or binge eating pattern

          -  Continuous glucocorticoid or anti-inflammatory treatment

          -  Uncontrolled thyroid disease

          -  Pregnancy, breastfeeding

          -  Psychiatric or cooperative problems or low compliance that is a contraindication from
             participating in the study

          -  Hiatal hernia &gt; 5 cm

          -  Currently participating in other study

          -  Any health issue that might put the patient at risk if the treatment is performed,
             judged by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ivo Boskoski, MD, PhD</last_name>
    <phone>+390630156580</phone>
    <email>ivo.boskoski@policlinicogemelli.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivo Boskoski, MD, PhD</last_name>
      <phone>00390630156580</phone>
      <email>ivo.boskoski@policlinicogemelli.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>December 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

